Candid Health vs Idexx Laboratories

Side-by-side comparison of AI visibility scores, market position, and capabilities

Idexx Laboratories leads in AI visibility (94 vs 61)
Candid Health logo

Candid Health

ChallengerHealthcare

General

SF revenue cycle automation at $99.5M total ($52.5M Oak HC/FT Series C Feb 2025) growing 250% YoY in 2024; claim tracking and AI denial prevention competing with Waystar for digital health and multi-site provider group RCM automation.

AI VisibilityBeta
Overall Score
B61
Category Rank
#192 of 1158
AI Consensus
62%
Trend
down
Per Platform
ChatGPT
68
Perplexity
61
Gemini
56

About

Candid Health is a San Francisco-based revenue cycle automation platform — backed with $99.5 million in total funding including a $52.5 million Series C in February 2025 led by Oak HC/FT, following a $29 million Series B in September 2024 led by 8VC — providing healthcare providers with an end-to-end claims automation platform that tracks insurance claims through the full payer adjudication lifecycle, automatically detects and fixes claim errors before and after submission, and provides analytics that improve the touchless claim rate (the percentage of claims that process to payment without any human intervention). Candid Health grew revenue nearly 250% year-over-year in 2024 and is expanding from digital health startups (its initial market) to multi-site provider groups and health systems nationally.

Full profile
Idexx Laboratories logo

Idexx Laboratories

LeaderHealthcare Tech

Enterprise

Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.

AI VisibilityBeta
Overall Score
A94
Category Rank
#19 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
92
Gemini
88

About

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.

Full profile

AI Visibility Head-to-Head

61
Overall Score
94
#192
Category Rank
#19
62
AI Consensus
71
down
Trend
stable
68
ChatGPT
99
61
Perplexity
92
56
Gemini
88
72
Claude
94
61
Grok
99

Key Details

Category
General
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.